News and Events

ONWARD Medical N.V. (Euronext : ONWD) (la « Société » ou « ONWARD Medical »), la société de technologie médicale qui crée des thérapies innovantes de stimulation de la moelle épinière pour restaurer le mouvement, la fonction et l’indépendance chez les personnes atteintes de lésions de la moelle épinière (SCI) et de troubles du mouvement, annonce aujourd’hui qu’elle a levé avec succès un montant de 20 millions d’euros de produit brut par le biais d’une procédure de construction accélérée d'un livre d'ordres à travers un placement privé auprès d’investisseurs institutionnels et de certains dirigeants et membres du Conseil d’administration de 4'307'641 nouvelles actions ordinaires (le « Placement Privé ») via les Teneurs de Livres Conjoints (tel que défini ci-dessous) et d’une offre au public séparée via la plateforme PrimaryBid auprès d’investisseurs particuliers en France de 136’803 actions ordinaires nouvelles (l’« Offre au Public »), représentant un total de 4’444’444 actions ordinaires nouvelles (ces actions, les « Actions Nouvelles » et, ensemble, le Placement Privé et l’Offre au Public , les « Offres »).

ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders, announces today that it successfully raised an amount of €20 million in gross proceeds by way of an accelerated bookbuild offering through a private placement with institutional investors, certain founders, and certain management and members of the Board of Directors of 4,307,641 new ordinary shares (the “Private Placement”) via the Joint Bookrunners (as defined below) and a separate public offering via the PrimaryBid platform with retail investors in France of 136,803 new ordinary shares (the “Public Offering”), representing a total of 4,444,444 new ordinary shares (such shares the “New Shares” and the Private Placement and the Public Offering together, the “Offerings”).

EINDHOVEN, the Netherlands — March 20, 2024, 5:40 pm CET — ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders, announces today the launch of a capital increase by way of an accelerated bookbuild offering through a private placement with institutional investors and certain founders, management and members of the Board of Directors (the “Private Placement”) via the Joint Bookrunners (as defined below) and a separate public offering via the PrimaryBid platform with retail investors in France (the “Public Offering”) of ordinary shares with a nominal value of EUR 0.12 each in the Company’s issued share capital (such shares the “New Shares” and the Private Placement and the Public Offering together, the “Offerings”).

EINDHOVEN, the Netherlands — March 18, 2024 — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces receipt of a positive report from a leading US-based medical equipment testing laboratory confirming its investigational ARC-EX System conforms to prevailing electrical standards, a requirement for commercial launch.